Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Oncology Nurses Need to Enhance Their Genetics and Genomics Competency

May 4th 2012

A pilot study has demonstrated a lag in the integration of genetics and genomics into nursing practice, which is an increasingly required professional skill for oncology nurses.

Managing Dermatologic Toxicities Associated With Targeted Therapies

May 1st 2012

Many targeted therapies are associated with dermatologic side effects; the monitoring and treating of these side effects should be done on an individual patient basis.

Dr. Spector on the Importance of Tumor Microenvironments

April 30th 2012

Dr. Neil Spector, from Duke Cancer Institute, Emphasizes the Importance of Studying Tumor Microenvironments

Landmark Study Redefines Breast Cancer Into 10 Subtypes

April 25th 2012

Researchers have determined that breast cancer can be classified into 10 different subtypes instead of four subtypes as previously thought.

Five Questions for Leonard M. Neckers, PhD

April 24th 2012

Leonard M. Neckers, PhD, has been studying the role of the molecular chaperone Hsp90 in signal transduction and the translational development of Hsp90-targeted anticancer agents for two decades.

Targeting Hsp90: Researchers Aim to Thwart Chaperones of the 'Guardian of the Proteome'

April 24th 2012

Hsp90 may be referred to as the 'guardian of the proteome,' since it regulates the correct structure and function of many of the important proteins encoded by our DNA.

Dr. Perez on the Mayo Clinic Breast Cancer Genomic Study

April 23rd 2012

Dr. Edith Perez, from the Mayo Clinic, Describes the Breast Cancer Translational Genomics Program

Breakthroughs in Targeted Therapies Not Applicable if Not Cost-Effective

April 20th 2012

Before the oncology treatment paradigm can move from a one-size-fits-all model to true personalized medicine, the medical establishment must find a cost-effective way to identify biomarkers.

Going Beyond the Label: Targeted Therapies Present New Questions in Clinical Use

April 18th 2012

The long-sought aim of treating malignant disease by targeting particular molecular abnormalities is becoming a reality in an increasing number of clinical settings.

USC Norris Comprehensive Cancer Center and Hospital: Groundbreaking Programs, Innovative Treatments

April 17th 2012

The USC Norris Comprehensive Cancer Center and Hospital has long enjoyed a national reputation as a leading resource for cancer research, treatment, prevention, and education.

Study Supports Combining c-MET Targeted Therapies With Angiogenesis Inhibitors

April 16th 2012

Agents that target the c-MET pathway may prove to have significant benefit when combined with inhibitors of angiogenesis.

Insights From Genomic Approaches to Oncology Discovery

April 12th 2012

The keynote address at the ASCO Genitourinary Cancers Symposium highlighted a collaborative effort to develop a comprehensive molecular classification of prostate cancer.

Optical Biomarkers Distinguish Risk Levels in Barrett's Esophagus

April 12th 2012

Optical biomarkers derived from nondysplastic metaplastic cells can detect the presence of high-grade dysplasia and adenocarcinoma from Barrett's esophagus.

Dr. Spector Discusses the Systemic Nature of Cancer

April 10th 2012

Dr. Neil Spector, from Duke Cancer Institute, Discusses the Systemic Nature of Cancer

Personalized Medicine: A Promising Future in Oncology Practice

April 10th 2012

This issue of Contemporary Oncology includes a focus on 2 challenging situations: management of metastatic TNBC and of advanced stage NSCLC.

Dual Inhibitors Explored in Triple-Negative Tumors

April 9th 2012

The use of advanced gene analysis techniques in a small group of women with triple-negative metastatic breast cancer has revealed activity in two pathways found in most patients with this subtype.

Targeted Therapies in Breast Cancer Offer Increasing Hope and Complexity

April 2nd 2012

As research progresses, optimal treatment of breast cancer will involve individualization of therapy to focus on specific targets driving each patient's cancer.

Dr. Perou on Next Generation Sequencing Technology

March 30th 2012

Dr. Charles Perou, from the UNC Lineberger Comprehensive Cancer Center, on Next Generation Sequencing Technology

Dr. Zelenetz Discusses DLBCL Targeted Therapies

March 29th 2012

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, on Targeted Therapies for Diffuse Large B-cell Lymphoma

Dr. Ellis Describes Breast Cancer Heterogeneity

March 27th 2012

Dr. Matthew Ellis, from Siteman Cancer Center, Describes Breast Cancer Heterogeneity